4-(2-bromoacetyl)benzamide | 83070-12-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-bromoacetyl)benzamide
• CAS: 83070-12-6
• 化学式: C₉H₈BrNO₂
• 分子量: 242.072
• InChiKey: CJNTYWZJTJBEQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  60.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基咪唑 、 4-(2-bromoacetyl)benzamide 以 乙腈 为溶剂， 生成 1-[2-(4-Carbamoyl-phenyl)-2-oxo-ethyl]-3-methyl-3H-imidazol-1-ium; bromide
  参考文献：
  名称：

  Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides

  摘要：

  Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides. Compounds 2 and 3 produced reductions of ca. 40% 2 h after doses of 100 mg/kg po. Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion. Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.

  DOI：

  10.1021/jm00130a013

文献信息

• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013093484A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药（其中字符如描述中所定义）。一般式(I)的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
• [EN] MYOSIN LIGHT CHAIN PHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHATASE DE CHAÎNE LÉGÈRE DE MYOSINE
  申请人：UNIV GEORGETOWN

  公开号：WO2009146013A1

  公开（公告）日：2009-12-03

  Novel myosin light chain phosphatase inhibitors, compositions containing them, methods of making and using them, and methods of using fluorescent myosin light chain phosphatase inhibitors are described.

  新型肌球蛋白轻链磷酸酶抑制剂，含有它们的组合物，制备和使用它们的方法，以及使用荧光肌球蛋白轻链磷酸酶抑制剂的方法被描述。
• [EN] IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS IMIDAZO[2,1]THIAZOL-3-ONE UTILES COMME AGENTS DE DIAGNOSTIC DE LA MALADIE D'ALZHEIMER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014026881A1

  公开（公告）日：2014-02-20

  The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula (I) wherein the variables are as defined in the claims. It has been shown that the present compounds may be used for binding and imaging tau aggregates and related b-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates, especially for use in binding and imaging tau aggregates in Alzheimer patients.

  该发明涉及式(I)中变量定义如权利要求中的咪唑[2,1-b]噻唑-3-酮衍生物。已经证明，这些化合物可用于结合和成像tau聚集体和相关的b-折叠聚集体，包括除其他外beta-淀粉样蛋白聚集体或α-突触核蛋白聚集体，特别是用于结合和成像阿尔茨海默病患者中的tau聚集体。
• Imidazo[2,1]thiazol-3-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150157739A1

  公开（公告）日：2015-06-11

  The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula wherein the variables are defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been shown that the present compounds may be used for binding and imaging tau aggregates and related b-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates, especially for use in binding and imaging tau aggregates in Alzheimer's patients.

  本发明涉及以下式子的咪唑[2,1-b]噻唑-3-酮衍生物，其中变量在此定义，或者其药学上可接受的酸加成盐，外消旋混合物或其对应的对映体和/或光学异构体。已经证明，这些化合物可以用于结合和成像tau聚集体和相关的β-折叠聚集体，包括除其他外的β-淀粉样聚集体或α-突触核蛋白聚集体，特别适用于在阿尔茨海默病患者中结合和成像tau聚集体。